Ascelia Q4: Plenty to look forward to in 2022 - Redeye

Ascelia continues to advance the pivotal Mangoral (Orviglance) study, which is also supported by recent publication at the RSNA and positive feedback from a food effect study. Ascelia has also secured a green light from FDA for the approaching phase 2 study combining Oncoral (daily irinotecan chemotherapy) with LONSURF advancing the partnership with Taiho Oncology. Ascelia has delivered on near term objectives recently, in our view.

Länk till analysen i sin helhet: https://www.redeye.se/research/832485/ascelia-q4-plenty-to-look-forward-to-in-2022?utm_source=finwire&utm_medium=RSS